David Schenkein, Cancer Doc Turned CEO, Aims to Build New Genentech Xconomy He was recruited later to oversee the clinical development and regulatory work for several of South San Francisco, CA-based Genentech's big cancer therapies like bevacizumab (Avastin), trastuzumab (Herceptin), and rituximab (Rituxan). Then, in May 2009 ... |
